Anti-Phencyclidine [6B5]
Catalogue Number: AB03257-1.1-ABA
| Manufacturer: | Vector Laboratories, Inc (ABA) |
| Type: | Recombinant Monoclonal |
| Alias: | PCP; CI-395; Angel dust; PCE; TCP; phenyl cyclohexyl piperidine; aryl cyclohexylamine; tenocyclidine; 1-(1-phenylcyclohexyl)piperidine; CAS: 77-10-1; CHEBI:8058; mAb6B5; ch6B5; ch-mAb6B5 |
| Shipping Condition: | Blue Ice |
| Unit(s): | 200 ug |
| Host name: | Mouse |
| Clone: | 6B5 |
| Isotype: | IgG1 |
| Immunogen: | The original antibody was generated from a mouse immunized with a phencyclidine analogue hapten 5-[N-(1'phenylcyclohexyl)amino]pentanoic acid (PCHAP) conjugated to bovine serum albumin. |
| Application: | ELISA, RIA, Ant |
Additional Text
Purification
Purified
Antibody Clonality
Recombinant Monoclonal
Storage Note
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Application Notes
The binding characterization of this antibody to 3[H]PCP was done using radioimmunoassay. The original IgG1 version of this antibody binds phencyclidine with an affinity of Kd= 1.3 nM. (PMID: 9618414). This antibody was useful in reversing PCP-induced central nervous system toxicity in laboratory animals. The Fab version of this antibody induced antagonism of behavioral effects of repeated intravenous PCP challenges. The Fab completely reversed all PCP-induced locomotor effects in a dose dependent manner. It also completely reversed the locomotor effects induced by two other structurally related potent analogs of PCP: 1-[1-(2-thienyl)cyclohexyl]piperidine and N-ethyl-1-phenylcyclohexylamine (PMID: 9618414). In a rat model for human acute PCP overdose, the antigen-binding fragment (Fab) of mAb6B5 causes a rapid and effective redistribution of PCP out of the brain (PMID: 8768723). This redistribution also produces a rapid recovery from the behavioral toxicity produced by PCP, TCP and PCE in rats (PMID: 8768723; 9618414). Preclinical studies in rats show that mAb6B5 can reverse or reduce the in vivo pharmacological effects of PCP and other potent aryl cyclohexylamines such as TCP. When tested in a rat model based on human chronic PCP use, a single low dose of mAb6B5 provides long-term protection against the adverse effects of PCP and significantly improves the general health status of the animals. Single 1 gm dose of mAb6B5 IgG has the capability of reducing the toxic effects of 1.29gm/day of PCP for 6-8 weeks (PMID: 12829731). The binding characterization of chimeric version of this antibody was done using ELISA (PMID: 18068094). This antibody can be used as an immunotherapeutic agent for PCP and PCP-like drug abuse.
AB03257-1.1 Datasheet
SUPPORT
outstanding technical support
PRODUCT
we offer a full product guarantee
DELIVERY
we offer free delivery to UK universities and non profit organisations